RASMUSSEN HENRIK S MD 4
4 · Allakos Inc. · Filed Apr 6, 2021
Insider Transaction Report
Form 4
Allakos Inc.ALLK
RASMUSSEN HENRIK S MD
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-04-06$111.68/sh−10,000$1,116,800→ 101,819 total - Sale
Common Stock
2021-04-01$114.40/sh−20,000$2,288,000→ 101,819 total - Exercise/Conversion
Stock Option (Right to buy)
2021-04-06−10,000→ 282,000 totalExercise: $1.16Exp: 2027-10-02→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2021-04-06$1.16/sh+10,000$11,625→ 111,819 total - Sale
Common Stock
2021-04-05$113.06/sh−20,000$2,261,200→ 101,819 total - Exercise/Conversion
Stock Option (Right to buy)
2021-04-05−20,000→ 292,000 totalExercise: $1.16Exp: 2027-10-02→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2021-04-05$1.16/sh+20,000$23,250→ 121,819 total - Exercise/Conversion
Common Stock
2021-04-01$1.16/sh+20,000$23,250→ 121,819 total - Exercise/Conversion
Stock Option (Right to buy)
2021-04-01−20,000→ 312,000 totalExercise: $1.16Exp: 2027-10-02→ Common Stock (20,000 underlying)
Footnotes (5)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $109.00 to $113.03 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- [F2]Includes shares of common stock purchased under the Company's 2018 Employee Stock Purchase Plan.
- [F3]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $111.24 to $115.90 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- [F4]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. This transaction was executed in multiple trades at prices ranging from $112.06 to $116.25 per share. The sale price reported represents the weighted average sale price . Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person hereby undertakes to provide full information regarding the number of shares sold at each separate price.
- [F5]On October 2, 2017, the Reporting Person was granted an option to purchase 392,000 ordinary shares pursuant to the Company's 2018 Equity Incentive Plan. The option vests as to one-fourth of the shares on October 2, 2018, and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.